EcoDrugPlus

Tumor Protein P53

Ensembl ID : ENSNBRG00000020507
Gene Symbol: TP53
3 Cross references
232 Possible Orthologues:

Type-2 Angiotensin Ii Receptor-Like

Ensembl ID : ENSNBRG00000019896
Gene Symbol: LOC102775661
3 Cross references
185 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSNBRG00000010211
Gene Symbol: TYR
4 Cross references
198 Possible Orthologues:

Tyrosinase-Like

Ensembl ID : ENSNBRG00000014852
Gene Symbol: LOC102779673
3 Cross references
202 Possible Orthologues:

Tyrosine 3-Monooxygenase-Like

Ensembl ID : ENSNBRG00000007209
Gene Symbol: LOC102780689
3 Cross references
187 Possible Orthologues:

Tyrosine-Protein Kinase Itk/tsk-Like

Ensembl ID : ENSNBRG00000018729
Gene Symbol: LOC102789162
3 Cross references
205 Possible Orthologues:

Tyrosine-Protein Kinase Jak1-Like

Ensembl ID : ENSNBRG00000014392
Gene Symbol: LOC102785183
3 Cross references
212 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSNBRG00000022657
Gene Symbol: LOC102779066
3 Cross references
194 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSNBRG00000009344
Gene Symbol: LOC102793574
3 Cross references
199 Possible Orthologues:

Tyrosine-Protein Kinase Lyn-Like

Ensembl ID : ENSNBRG00000019416
Gene Symbol: LOC102780153
3 Cross references
195 Possible Orthologues:

Tyrosine-Protein Kinase Syk-Like

Ensembl ID : ENSNBRG00000006773
Gene Symbol: LOC102785614
3 Cross references
200 Possible Orthologues:

Tyrosine-Protein Kinase Fyna-Like

Ensembl ID : ENSNBRG00000023178
Gene Symbol: LOC102784836
3 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).